Necroptosis in Both Tumour and Stromal Compartments Determines Responsiveness to Immunogenic Cell Death-based Immunotherapy

This dataset contains the raw and processed data supporting the study investigating the role of immunogenic cell death (ICD) and necroptosis in enhancing immunotherapy responses in triple-negative breast cancer (TNBC). The data were generated using a Brca1⁻/⁻p53⁻/⁻ organoid-derived TNBC mouse model that recapitulates the immune landscapes of basal-like tumours. The dataset includes experimental data assessing tumour response, immune infiltration, and therapeutic efficacy following immune checkpoint blockade (anti–PD-1), IAP antagonism, caspase blocking and STING agonist treatment. Genetic perturbation experiments targeting key necroptosis regulators (including Ripk1 and Mlkl) in tumour and stromal compartments are also represented, enabling mechanistic dissection of tumour-intrinsic and microenvironmental contributions to therapy response. These data demonstrate that RIPK1-driven necroptosis is required for effective ICD and synergistic antitumour immunity, and that coordinated necroptosis in both tumour and stromal cells is critical for durable tumour control and immune memory. Additionally, the dataset captures experiments showing that immunologically “cold” tumours can be sensitised to ICD-based immunotherapy through STING pathway activation.